Case Summary (G.R. No. 194872)
Applicable Law
The case is primarily governed by the provisions of Republic Act No. 8293, known as the Intellectual Property Code of the Philippines, particularly Section 76, which defines and outlines the civil actions for patent infringement.
Factual Background
Warner Lambert, as the owner of three patents concerning Atorvastatin and its crystalline form, discovered that Sahar had obtained a Certificate of Product Registration (CPR) from the Food and Drug Administration (FDA) for its own product, Atopitar. This led to the assertion that Sahar’s product infringed upon Warner Lambert’s patents. Pfizer, upon realizing that Sahar was marketing Atopitar, which was not manufactured by Warner Lambert, initiated a legal complaint against Sahar for patent infringement, seeking not only damages but also injunctive relief to prevent further distribution of Atopitar.
Regional Trial Court Ruling
The Regional Trial Court (RTC) denied the respondents' request for a preliminary injunction. The RTC’s reasoning was that granting such an injunction could prematurely resolve the main issues of the case concerning damages and patent validity. Consequently, the RTC’s orders allowed Sahar to continue its operations until the main complaint was resolved.
Court of Appeals Ruling
Upon appeal, the Court of Appeals reversed the RTC's ruling. It found that respondents, Warner Lambert and Pfizer, had established their right to a preliminary injunction. The CA determined that Sahar was indeed infringing upon existing patents owned by Warner Lambert and that confusion was being caused in the medical market regarding the branding of Lipitor (the product of Warner Lambert and Pfizer) in the presence of Sahar's Atopitar. The CA issued a writ of preliminary injunction restraining Sahar from selling or distributing Atopitar during the pendency of the patent infringement case.
Subsequent Developments
While the appeal was ongoing, the RTC eventually dismissed the original patent infringement case filed by Warner Lambert and Pfizer on March 11, 2011, due to a lack of cause of action. This led to further appeals by the respondents. On November 5, 2013, the CA found Sahar liable for patent infringement and ordered it to pay damages, making the writ of preliminary injunction permanent and directing the seizure and forfeiture of infringing products.
Supreme Court's Resolution
The Supreme Court ultimately dismissed Sahar's petition on the basis of mootness. The decision in the CA that made the
...continue readingCase Syllabus (G.R. No. 194872)
Introduction
- The case involves a petition for review on certiorari filed by Sahar International Trading, Inc. against Warner Lambert Co., LLC and Pfizer, Inc. concerning the issuance of a writ of preliminary injunction regarding patent infringement.
- The Court of Appeals' decisions are contested, which annulled prior orders of the Regional Trial Court (RTC) and granted the injunction against Sahar.
Background of the Case
- Warner Lambert, a foreign corporation, holds three Philippine patents related to Atorvastatin and Atorvastatin Calcium, set to expire between 2009 and 2019.
- Atorvastatin is a pharmaceutical used to manage cholesterol levels and reduce the risk of cardiovascular diseases.
- Pfizer is the exclusive licensee of Warner Lambert in the Philippines, responsible for marketing and distributing products under these patents.
Discovery of Patent Infringement
- In 2005, Pfizer discovered that Sahar had obtained a Certificate of Product Registration (CPR) for Atorvastatin Calcium marketed as "Atopitar."
- Sahar's advertisements indicated that Atopitar was manufactured by Geofman Pharmaceuticals of Pakistan, not affiliated with Warner Lambert or Pfizer.
- Pfizer accused Sahar of patent infringement, asserting that Sahar's activities violated Warner Lambert's patents on Atorvastatin Calcium.
Initial Legal Proceedings
- Warner Lambert and